Patience is wearing thin on Capitol Hill, both with drug companies that insist on maintaining high U.S. list prices and with congressional inaction on what's "one helluva problem," as Sen. John Kennedy (R-La.) described those prices at a Senate Judiciary Committee hearing Tuesday.